NDAORALSUSPENSION
Approved
Jul 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ATMEKSI (methocarbamol) by Baxter International is 12. First approved in 2025.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATMEKSI (methocarbamol) is an oral muscle relaxant suspension approved by the FDA on July 30, 2025, for the treatment of muscle pain and associated discomfort. The mechanism of action is not fully established but is believed to involve general CNS depression rather than direct action on muscle tissue. It is rapidly absorbed with a median Tmax of 0.66 hours and has a short elimination half-life of approximately 1.3–1.5 hours.
Growth18.1 years to LOE
Early-stage product in growth phase with opportunity to build market presence; commercial team expansion likely as market penetration increases.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of methocarbamol in humans has not been established but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. 12.3…
Worked on ATMEKSI at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.